Accropeutics' RIPK2 Inhibitor AC-101 Receives FDA Clearance for Phase II Trial in Ulcerative Colitis

Accropeutics Inc. (Accropeutics), a clinical-stage biotech company with a focus on molecular mechanisms of regulated cell death and related pathogenesis in...

December 16, 2024 | Monday | News
A2A Pharmaceuticals Advances Phase 1 Clinical Trial of TACC3 Inhibitor A0-252 in Ovarian, TNBC, and Endometrial Cancers

A2A Pharmaceuticals, Inc. ("A2A or "the company"), a clinical-stage pioneering biopharmaceutical company focused on developing innovative cancer therapies,...

December 13, 2024 | Friday | News
Imlunestrant Shows Significant PFS Improvement in Phase 3 EMBER-3 Trial for ER+ HER2- Advanced Breast Cancer

Eli Lilly and Company (NYSE: LLY) announced results from the Phase 3 EMBER-3 study of imlunestrant, an investigational, oral selective estrogen recept...

December 13, 2024 | Friday | News
FDA Grants Fast Track Designation to Sanofi’s Combination Vaccines for Influenza and COVID-19 in Older Adults

The US Food and Drug Administration has granted Fast Track designation to two Sanofi combination vaccine candidates to prevent influenza and COVID-19 infec...

December 13, 2024 | Friday | News
AstraZeneca and Merck Announce Six-Year Data from OlympiA Trial, Showing LYNPARZA Significantly Improves Survival in BRCA-Mutated Early Breast Cancer

 AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced long-term results from the OlympiA Phase 3 trial w...

December 13, 2024 | Friday | News
Advancing Healthspan for All: Dr. Mehmood Khan Spotlights Aging Science Trends for 2025

  In an exclusive interview with BioPharma Boardroom, Dr. Mehmood Khan, Chief Executive Officer of Hevolution Foundation, shares insights into the tr...

December 12, 2024 | Thursday | News
Sanofi Advances First Non-mRNA Flu-COVID Combination Vaccines with FDA Fast Track Designation

First non-mRNA combination vaccine candidates that include two already licensed vaccines to prevent influenza and COVID-19 infections Two phase 1/2 cl...

December 11, 2024 | Wednesday | News
Arvinas and Pfizer Report Promising Preliminary Data for Vepdegestrant and Abemaciclib Combo in ER+/HER2- Breast Cancer

Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) announced preliminary data from the ongoing Phase 1b portion of the TACTIVE-U sub-study of vepdege...

December 11, 2024 | Wednesday | News
Lilly’s Pirtobrutinib Shows Strong Efficacy in Phase 3 BRUIN CLL-321 Trial for BTK-Inhibitor Pre-Treated CLL/SLL Patients

Eli Lilly and Company (NYSE: LLY) announced results from the Phase 3 BRUIN CLL-321 trial evaluating pirtobrutinib, a non-covalent (reversible) Bruton'...

December 10, 2024 | Tuesday | News
AbbVie’s Tavapadon Demonstrates Strong Efficacy in Phase 3 TEMPO-2 Trial for Early Parkinson’s Disease

AbbVie (NYSE: ABBV) announced positive topline results from its pivotal Phase 3 TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose monot...

December 10, 2024 | Tuesday | News
Merck's KEYTRUDA® Combined with LYNPARZA® Achieves Key Milestone in Phase 3 Trial for Advanced Ovarian Cancer

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the Phase 3 KEYLYNK-001 trial evaluating KEYTRUDA ® (...

December 10, 2024 | Tuesday | News
Merck’s Zilovertamab Vedotin Achieves 100% Complete Response in Phase 2 DLBCL Trial, Setting Stage for Phase 3

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the first presentation of data from the Phase 2 waveLINE-007 trial evalu...

December 09, 2024 | Monday | News
Kite Presents Groundbreaking Real-World Data at ASH, Showcasing Yescarta®'s Impact on Relapsed/Refractory Large B-Cell Lymphoma

Kite, a Gilead Company (Nasdaq: GILD), announced findings from three new analyses for Yescarta ® (axicabtagene ciloleucel) that demonstrate i...

December 09, 2024 | Monday | News
Genentech Presents Positive Five-Year Follow-Up Data from POLARIX Study on Polivy® Combination for Untreated DLBCL

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced data from a five-year follow-up of the pivotal Phase III POLARIX study evalu...

December 09, 2024 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close